MarketCapExport financials
Kinnate Biopharma (KNTE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Kinnate Biopharma Balance Sheet 2023-2011 | KNTE
Brief overview of Kinnate Biopharma 's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2019 to 2023.
The asset base grew from $77.6 million to $173.6 million, or +123.7%. Average annual growth of roughly 22.3% was strong.
Liabilities grew more slowly than assets: -85% versus +123.7%. Expansion relied more on equity, improving funding quality.
The equity ratio reached 91.8% from . A high capital share reduces dependence on liabilities.
Negative net debt of -$53.8 million means cash holdings are larger than debt obligations.
The balance sheet includes a negative accumulated result of -$372 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
Kinnate Biopharma shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Kinnate Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-53.8 M | -25.1 M | - | -365 M | -76.5 M | -7 M | - | - | - | - | - | - | - |
Long Term Debt |
2.28 M | 3.19 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
892 K | 991 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 93.1 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
12 M | 17.2 M | 12.4 M | 7.3 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
14.3 M | 20.4 M | 12.4 M | 7.3 M | 95.1 M | 467 K | - | - | - | - | - | - | - |
Retained Earnings |
-372 M | -259 M | -143 M | -53.3 M | -17.6 M | -7.63 M | - | - | - | - | - | - | - |
Total Assets |
174 M | 279 M | 367 M | 401 M | 77.6 M | 8.08 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
57 M | 29.3 M | 116 M | 365 M | - | - | - | - | - | - | - | - | - |
Book Value |
159 M | 258 M | 354 M | 393 M | -17.5 M | 7.61 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
159 M | 223 M | 319 M | 393 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Kinnate Biopharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.52 M | 2.74 M | 2.96 M | 3.19 M | 3.45 M | 3.7 M | 4.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
18.3 M | 18.5 M | 21.1 M | 20.4 M | 18.8 M | 15.2 M | 17.8 M | 12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-355 M | -324 M | -292 M | -259 M | -228 M | -197 M | -170 M | -143 M | -117 M | -92.2 M | -70.8 M | -53.3 M | -53.3 M | -53.3 M | -53.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
191 M | 216 M | 244 M | 279 M | 302 M | 324 M | 349 M | 367 M | 386 M | 405 M | 386 M | 401 M | 401 M | 401 M | 401 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
51.7 M | 34.5 M | 73.6 M | 29.3 M | 34.5 M | 35.1 M | 33.1 M | 116 M | 135 M | 133 M | 182 M | 365 M | 365 M | 365 M | 365 M | 76.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
172 M | 198 M | 223 M | 258 M | 283 M | 309 M | 331 M | 354 M | 386 M | 405 M | 386 M | 401 M | 401 M | 401 M | 401 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
172 M | 198 M | 223 M | 223 M | 248 M | 274 M | 296 M | 319 M | 341 M | 361 M | 379 M | 393 M | 393 M | 393 M | 393 M | -17.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Kinnate Biopharma , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
